Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India

Indian Journal of Medical Research

Volumn 132, Issue 9, 2010, Pages 287-294

  Panjwani, Poonam ^a   Epari, Sridhar ^a   Karpate, Arti ^a   Shirsat, Hemlata ^a   Rajsekharan, Preetha ^a   Basak, Ranjan ^a   Shet, Tanuja ^a   Chinoy, Roshni ^a   Chacko, Roy ^a   Gursale, Sampada ^a   Baraskar, Nayana ^a   Gupta, Sudeep ^b   Hawaldar, Rohini ^a   Desai, Sangeeta ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b Department of Medical Oncology ^*  (India)

Author keywords

Breast cancer; Fluorescent in situ hybridization (FISH); HER2 neu; Immunohistochemistry (IHC); Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; BIOLOGICAL MARKER; HER2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDIA; MAJOR CLINICAL STUDY; MALE; BREAST TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; EVALUATION; GENETICS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; INDIA; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY;

EID: 77957101699     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Walker RA. Use and assessment of diagnostic and predictive markers in breast pathology. Curr Diagn Pathol 2007; 13: 126-34.
2. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring and treatment of primary and metastatic breast cancer. Oncologist 2006; 11: 541-52.
3. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cole RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 resting in breast cancer. J Clin Oncol 2007; 25: 118-45.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metatstatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
5. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2 positive early breast cancer. Oncologist 2006; 11 (Suppl 1): 4-12.
6. Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L. Lapatinib in breast cancer. Ann Oncol 2007; 18 (Suppl 6): vi26-30.
7. Paik S, Bryant J, Tan-Chiu E. Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94: 852-4.
8. Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer - the present. Histopathology 2008; 52: 82-90.
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
10. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291: 1972-7.
11. Crowe JP, Patrick RJ, Rybicki LA, Escobar PF, Weng D, Budd GT, et al. A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. Breast 2006; 15: 728-35.
12. Prati R, Apple SK, He J, Gornbein JA, Chang HR. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J 2005; 11: 433-9.
13. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Limbergen V, et al. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005; 16: 1755-61.
14. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006; 13 (Suppl 1): S15-S24.
15. Pinto AE, André S, Pereira T, Nóbrega S, Soares J. c-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol 2001; 12: 525-33.
16. Shou J, Massarweh S, Osborne CK, Wakerling AE, Ali S, Weiss H, et al. Mechanisms of Tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-35.
17. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-81.
18. Merola R, Mottolese M, Orlandi G, Vico E, Cognetti F, Sperduti I, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer 2006; 42: 1501-6.
19. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005; 11: 6598-607.
20. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999; 17: 1974-82.
21. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001; 7: 1669-75.
22. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility of trastuzumab therapy: apparent Immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19: 2714-21.
23. Hammock L, Lewis M, Phillips C, Cohen C. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 2003; 34: 1043-7.
24. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006; 24: 3032-8.
25. Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, et al. Detection of HER-2/neu (c-erbB-2) DNA amplification in primary breast carcinoma: interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 2001; 92: 2965-74.
26. Barrett C, Magee H, O'Toole D, Daly S, Jeffers M. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? J Clin Pathol 2007; 60: 690-3.
27. Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 2005; 29: 1221-7.
28. Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez GM, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 2005; 11: 4393-9.